AstraZeneca Pharma India Limited (NSE:ASTRAZEN)

Market Cap	201.93B -7.8%
Revenue (ttm)	24.30B +31.0%
Net Income	1.70B -7.5%
EPS	67.85 -7.5%
Shares Out	n/a
PE Ratio	119.05
Forward PE	n/a
Dividend	36.00 (0.45%)
Ex-Dividend Date	Jul 31, 2026

Volume	6,725
Open	7,966.00
Previous Close	8,090.00
Day's Range	7,930.00 - 8,050.00
52-Week Range	7,551.50 - 9,849.50
Beta	0.25
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 10, 2026

About AstraZeneca Pharma India

AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, markets, and trades in pharmaceutical products in India and internationally. It provides medicines for cardiovascular, renal, metabolic, and immunological conditions; oncology medicines under the TAGRISSO, Lynparza, ENHERTU, IMFINZI, and Zoladex brand names; rare diseases medicines under the Koselugo brand name; and respiratory medicines under the Symbicort and Fasenra brand names. The company also offers medicines for diabetes; and clinical trial services. The company...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1979
• Employees: 760
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: ASTRAZEN

Financial Performance

In fiscal year 2026, AstraZeneca Pharma India's revenue was 22.76 billion, an increase of 32.59% compared to the previous year's 17.16 billion. Earnings were 1.88 billion, an increase of 62.02%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 11, 2026

Data Sources Report a data error